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Abstract
Many factors, including relatively young age of thyroid cancer diagnoses and improved survival, have led to 
increased concerns about the occurrence of second primary malignancies. This paper describes the pattern of 
occurrence of second primary malignancies in patients who were treated for malignant thyroid neoplasms in an 
Indian hospital. There were 21 affected patients of the approximately 4500 seen over 25 years. Most of the second 
primary cancers are solid tumors, and when nonthyroid cancers are the second tumors, ductal carcinoma of the 
female breast is the most common. Most of these tumors have very short detection intervals (including synchronous 
occurrences), suggesting that therapy with internal radiation was not contributory to the tumor development. When 
thyroid malignancies were the second primary cancers, they usually follow radiotherapy to the head and neck 
region for treatment of the first primary tumor and tend to be of aggressive histologic types than the common well 
differentiated thyroid carcinomas.
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Introduction
Improved early detection of first malignancies and 
availability of more effective treatment modalities have 
resulted in prolonged survival, with consequent increased 
risk of secondary malignancies.[1] Also increasing 
incidence, improved prognosis and the relatively young 
age at thyroid cancer diagnoses coupled with the 
employment of radioiodine in diagnostic and therapeutic 
doses have led to concerns about the development of 
second primary malignancies in thyroid cancer patients. 
Thyroid cancers have been known to result in patients 
exposed early in life to radiation from radiotherapy. In 
addition, they have also been known to arise as second 
primary malignancies after other cancers. Some organs 
concentrate radioiodine, e.g., salivary gland, colon and 
bladder[2-4] while others, e.g., breast tissue[5] express sodium 
iodide symporter, a membrane glycoprotein important in 
the active transport of iodide (including radioactive 
iodide) in the thyroid gland. This potentially exposes 
these organs to significant radiation and the attendant 
risk of radiation-induced malignant transformations. 
Other studies suggest a common genetic predisposition 
to explain the associations[6] of thyroid carcinomas and 
other identified comalignancies. This paper describes 
the pattern of second primary malignancies in affected 
patients of the 4500 patients treated for thyroid 
carcinoma at the All India Institute of Medical Sciences 
within the past 25 years. All patients already had 
thyroidectomies ranging from hemi-thyroidectomy to 
total thyroidectomy. Radioiodine-131, in diagnostic and 
therapeutic doses was also given to all patients according 
to institutional protocols.
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Materials and Methods
A retrospective search through 4500 case notes of patients 
seen at the nuclear thyroidology clinic of the All India 
Institute of Medical Sciences within the past 25 years yielded 
21 patients (0.45%) with second primary malignancies. All 
but three cases had thyroid carcinoma as the first primary 
cancer. The variables analyzed included age (at presentation 
for the second malignancy), sex, past history of external 
beam radiotherapy in childhood or youth especially to 
the head and neck, and thyroid cancer presentation. 
Other variables analyzed include the histology of the 
thyroid lesion, immediate past history of external beam 
radiotherapy, presence or absence of metastasis of thyroid 
cancer and finally the site of second primary neoplasm. The 
synchronous or metachronous occurrence of the second 
primary malignancies as well as their detection intervals 
between the first and the second malignancies were also 
analyzed.
Results
There were a total of 21 patients with second malignancies 
discovered in the search, representing 0.45% of the 
approximately 4500 cases [Table 1]. Of these 11 (52.4%) 
were females while 10 (47.6%) were males (that is a female 
to male of 1.1:1). The mean age was 49.3 years. Females 
were found to be older at presentation with a mean age of 
52.5 years compared to 45.8 years found in men. A total 
of 18 out of our 21 patients presented with thyroid cancer 
as the first malignancy. The rest three patients had thyroid 
cancer as a second primary malignancy. The histopathology 
from the thyroidectomy specimens among those with 
thyroid carcinoma as the first primary malignancy showed 
that 12 patients or 66.7% had papillary thyroid cancer, 
3 (16.7%) had follicular variant of papillary thyroid cancer 
(FVPTC), while 3 (16.7%) had follicular carcinoma of the 
thyroid. As mentioned earlier, three patients had a reverse 
situation where thyroid carcinomas were discovered down 
the line after the patients had been diagnosed and treated 
for other malignancies. All three had received external 
beam radiotherapy (EBRT) to the head and neck region as 
part of the treatments for their first cancers. In this group of 
patients, the second primary thyroid cancers consisted each 
of follicular carcinoma of thyroid (FCT) with Hurthle cells, 
papillary cancer thyroid (PCT) and insular cell carcinoma. 
Hurthle and insular cell cancers are aggressive malignancies 
and these represented 2 of the 3 tumors.
Among the 18 patients who had thyroid cancer as first 
malignancies, of which 17 are solid tumors and one a 
leukemia (CML), about 16.7% of malignancies occurred in 
the region of the head and neck, specifically one each for 
tongue, lip, and eye.
In 5 patients out of these 18 patients, there was synchronous 
detection of co-malignancies. When considered as a 
group, patients with short T1T2 intervals of 3 years and 
less (including synchronous tumors, T1T2 = 0) were 
13/18 (72.2%) and has a mean T1T2 interval of 0.8 years. 
Table 1: Distribution of first and second primary tumors
Age (years) Sex 2nd Primary Ca (T2) Age at first presentation (yrs) 1st Primary Ca (T1) T1T2 interval (years)
48 F Inv D. Ca, breast 45 PCT 3
35 F Inv D. Ca, breast 19 PCT 14
39 M FCT with Hurtle Cells 8 HD 31
46 F Ca tongue 46 PCT 0#
30 M CML 16 PCT 14
46 F Chondrosarcoma of Femur 45 PCT 1
55 F PCT 48 Inv D. Ca, breast 7
50 F Inv D. Ca, breast 50 FVPCT 0#
59 M Adenocarcinoma of Rectum 51 PCT 8
50 M Adenocarcinoma of Lungs 42 PCT 8
48 F Inv D. Ca, breast 48 FCT 0#
35 F Inv D. Ca, breast 34 PCT 1
52 F Ca ovary 51 FCT 1
55 M Renal cell Ca 47 PCT 8
78 M Squamous cell Ca, lip 78 PCT 0#
65 F Malignant melanoma of eye 64 FVPCT 1
36 M Insular cell Ca, thyroid 17 Ca larynx 19
67 M Ca prostate 66 FCT 1
60 F Phylloides tumor, breast 60 FVPCT 0#
38 F Inv D. Ca, breast 37 PCT 1
44 M HD 43 PCT 1
HD=Hodgkin’s disease; FCT=Follicular cancer of the thyroid; FVPCT=Follicular variant of papillary cancer of the thyroid; PCT=Papillary cancer of the thyroid; 
Ca=Carcinoma; Inv D. Ca=invasive ductal carcinoma; #=synchronous tumor
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The rest (5/18) had T1T2 of 8 years and above, with a 
mean of 10.3 years.
In all these 18 patients, malignancies of the breast 
(including phylloides tumor) were the commonest, 
accounting for 7 (38.9%). All were female breast tumors. 
When only females are considered, the breast tumors made 
up 7/11 (63.6%) of cases.
Discussion
Though they occur and are to be kept in mind by oncologists, 
second primary malignancies in thyroid cancer patients 
cannot be said to be frequent. In this study, about 0.45% of 
the patients had a second primary malignancy. Most of the 
malignancies occurring in association with thyroid cancers 
in this study are solid tumors; all cases but one being so; the 
exception is the single case of chronic myeloid leukaemia. 
Thyroid cancers are treated mainly with internal radiation. 
It has been recognized that radiotherapy induces mostly solid 
tumors and that the risk of leukemia following radiation 
is considerably smaller than after chemotherapy.[1] Breast 
cancer associated with female thyroid cancer appears to 
be of concern judging from this series where seven of such 
cases were seen. Many studies evaluating the risk of breast 
cancer following thyroid cancer have generally found a 
significant but modest (20-30%) overall increased risk.[6-14] 
Other studies have found that this increased risk is higher 
in younger thyroid cancer patients[6,8,9,11] and that itrogenic 
effects do not appear to explain these associations.[7,8,10,11] 
In one of our patients there was a 7-year interval between 
the discovery and treatment of a breast cancer and the 
subsequent discovery of a second cancer in the thyroid 
gland. However, in most of the affected patients, thyroid 
and breast cancers were either synchronously detected or 
detected within three years. In carcinogenesis, this interval 
is too short for one to even begin to look at the therapeutic 
radiation as being of etiologic significance.
As earlier stated, three patients in our study (two males 
and one female) presented with an initial non-thyroid 
malignancy. Later on they were diagnosed with thyroid 
cancer. One thing common to these patients is that they 
had all received adjuvant external beam radiotherapy to the 
head and neck region as part of the treatments for their first 
cancers (Hodgkin’s lymphoma, laryngeal carcinoma, and 
breast cancer, respectively). These cases appear to suggest 
that radiation in the form of external beam radiotherapy 
(EBRT) had some role in the initiation of their thyroid 
cancers. A study[11] found that ten of twenty patients with 
a history of receiving EBRT to the head and neck region 
later on developed thyroid malignancy. Radiation-induced 
thyroid neoplasia in children is a recognized result of direct 
irradiation to the thyroid as seen in treatments for Hodgkin’s 
disease.[15,16] Apart from finding thyroid cancer in this group 
of patients, the tumors were mostly of aggressive types. In 
addition these patients had peculiarly long T1T2 times 
(31 and 19 years respectively). Though we are cautious 
(due to our small sample size) in reaching a conclusion 
concerning the role of head and neck EBRT in the initiation 
of aggressive thyroid cancer histologies, this result however 
agrees with similar ones which concluded that EBRT to the 
head and neck in the younger age group[17] increases the 
risk of thyroid carcinomas. Again it appears that the males 
within this subset had much longer T1T2 times compared 
to the lone female. Again the small sample size prevents any 
conclusions concerning the influence of patient’s gender 
on T1T2 times.
For over half a century, radioiodine (131I) has been used in 
the diagnosis and treatment of patients with papillary and 
follicular thyroid carcinoma.[7] With respect to the risk of 
development of second primary cancers in adult patients 
in whom radioiodine 131I has been used in diagnostic 
doses[18] as well as in the treatment of benign thyroid 
conditions like hyperthyroidism,[19,20] much larger doses 
are deployed in the treatment of thyroid malignancies, 
e.g., follicular and papillary thyroid cancers of the thyroid. 
This has consequently resulted in significant patient 
radiation exposure.[7] Paradoxically, among other cancers 
differentiated thyroid carcinomas present a relatively benign 
biology, resulting in long life expectancy. It is feared that this 
may allow sufficient time for the patient to develop another 
cancer at another site.[21] To buttress this, an autopsy series 
found that 50% of patients who had thyroid cancer were 
discovered to have another entirely separate cancer.[22]
Apart from the fact that sodium iodide symporter 
(a membrane glycoprotein that mediates active iodide 
transport in the thyroid) finds extrathyroidal expression in 
places like the salivary gland, stomach and breast, ingested 
radioiodine used in the treatment of thyroid cancer is 
eliminated from the body via the faeces in the digestive 
tracts, in saliva and urine. Minor excretion occurs through 
sweat. These pathways potentially expose the related 
organs to ionizing radiation,[23] which may possibly initiate 
carcinogenesis at these sites. Even so the association, for 
example, between the renal excretion of radioiodine and 
kidney cancers has received less attention.[24] In this study, 
we found only one case of renal cancer and one case of 
prostatic cancer as second malignancies in patients with 
thyroid carcinoma and treated with radioiodine. Some 
workers consistently report a substantial increased risk 
of two or more fold for kidney cancer following thyroid 
cancer. [7,11,12,25] In one follow-up study on 2968 people 
with thyroid cancer, an increase in kidney, endocrine, and 
nervous system tumors was found.[26] Also the increased risk 
of second primary kidney cancer has been shown previously 
in population based studies,[27] but does not appear to be 
related to 131I exposure.[7] A recent study[28] has identified 
a familial association between papillary thyroid cancer 
and papillary renal neoplasia. A mutant susceptibility 
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gene designated as FPTC/PRN has been implicated. We 
found two cases of second malignancies involving the 
gastrointestinal system. One patient had cancer of the 
tongue while the other had cancer of the rectum.
Conclusion
The occurrence of other malignancies with thyroid 
carcinoma in patients remains an important thing to bear in 
mind and therefore patients should be adequately screened. 
Second malignancies in thyroid cancer patients, though not 
frequent, is important to note. Female breast carcinoma is 
the highest occurrence in this study, this is significant since 
there is only a slight preponderance of females among the 
cases. When thyroid carcinoma is the first to be diagnosed, 
the second primaries do not appear to be often related 
with the radioiodine therapy given for the treatment of the 
thyroid tumors as the interval between diagnoses is usually 
too short for de novo tumorigenesis. In contrast, when thyroid 
carcinomas are the second primary tumors, they appear to be 
causally related to the treatment given for the first primary 
malignancies and they tend to be of aggressive types. As in 
all disease conditions early detection may provide the hope 
of a better outcome for such patients. Therefore the need 
for extended surveillance among patients who had received 
EBRT to the head and neck regions as treatment for a first 
cancer cannot be overemphasized.
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